IP Library Granted Patent US 9,982,286
Granted Patent B2
US 9,982,286 · App. 15/235,453 · Granted May 29, 2018

Medium for the protein-free and serum-free cultivation of cells

Inventors: Manfred Reiter (Vienna, AT); Wolfgang Mundt (Vienna, AT); Friedrich Dorner (Vienna, AT); Leopold Grillberger (Vienna, AT); Artur Mitterer (Orth/Donau, AT)
Assignees: Baxalta Incorporated; Baxalta GmbH
C12P21/00C07K14/755C12N5/005C12N5/0037C12N5/0043C12N5/0682C12N2500/05C12N2500/32C12N2500/38C12N2500/46C12N2500/60C12N2500/76C12N2500/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,982,286
App. No.
15/235,453
Granted
May 29, 2018
Kind
B2
Abstract

A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate.

Claims (14)

1. A method for increasing productivity of a recombinant protein in a cell culture, the method comprising:

culturing mammalian cells that express the recombinant protein in an animal protein-free and serum-free cell culture medium; and

adding more than 10 wt. % ultrafiltered soy hydrolysate based on the total dry weight of the medium to the animal protein-free and serum-free cell culture medium,

wherein at least 40% of the soy hydrolysate has a molecular weight of ≤500 daltons.

2. The method of claim 1 , wherein at least 50% of the soy hydrolysate has a molecular weight of ≤500 daltons.

3. The method of claim 1 , wherein at least 55% of the soy hydrolysate has a molecular weight of ≤500 daltons.

4. The method of claim 1 , wherein the soy hydrolysate has an endotoxin content of <500 U/g.

5. The method of claim 1 , wherein the mammalian cells are CHO cells or BHK cells.

6. The method of claim 1 , wherein the recombinant protein is selected from the group consisting of: Factor II, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Protein S, Protein C, activated forms of these factors, and vWF.

7. The method of claim 6 , wherein the recombinant protein is Factor VIII.

8. The method of claim 1 , wherein the medium comprises an amino acid.

9. The method of claim 8 , wherein the amino acid is selected from the group consisting of L-asparagine, L-cysteine, L-cystine, L-proline, L-tryptophan, L-glutamine and mixtures thereof.

10. The method of claim 1 , wherein the medium further comprises: 1 to 100 g/L synthetic minimal medium; 0.05-1 g/L glutamine; 0.0005-0.05 g/L ascorbic acid; 0.1-10 g/L NaHCO 3 ; 0.0005-0.05 g/L ethanolamine; and 1-15 μg/L sodium selenite.

11. The method of claim 1 , wherein the cells are cultured in a bioreactor.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2017
From: BAXALTA INNOVATIONS GMBH
To: BAXALTA INCORPORATED; BAXALTA GMBH
Reel/Frame 042084/0971 →
Priority Claims (1)
AT A1659/99 · Sep 28, 1999 · national
Continuity (6)
Continuation 14231221 · Mar 31, 2014
Continuation 13198476 · Aug 4, 2011
Continuation 11841915 · Aug 20, 2007
Continuation 10405794 · Apr 1, 2003
Continuation 09672240 · Sep 28, 2000
Related Publication 20160369316A1 · Dec 22, 2016